24 Facts About Olanzapine

Olanzapine is an atypical antipsychotic primarily used to treat schizophrenia and bipolar disorder.

Olanzapine was patented in 1991 and approved for medical use in the United States in 1996.

Olanzapine appears to be effective in reducing symptoms of schizophrenia, treating acute exacerbations, and treating early-onset schizophrenia.

Olanzapine caused less extrapyramidal side effects and less akathisia, but caused significantly more weight gain, serum cholesterol increase, and triglyceride increase than haloperidol.

Olanzapine is recommended by the National Institute for Health and Care Excellence as a first-line therapy for the treatment of acute mania in bipolar disorder.

Related searches

Olanzapine has been shown to be helpful in addressing a range of anxiety and depressive symptoms in individuals with schizophrenia and schizoaffective disorders, and has since been used in the treatment of a range of mood and anxiety disorders.

Olanzapine is no less effective than lithium or valproate and more effective than placebo in treating bipolar disorder.

Olanzapine has been studied for the treatment of hyperactivity, aggressive behavior, and repetitive behaviors in autism.

Olanzapine is frequently prescribed off-label for the treatment of insomnia, including difficulty falling asleep and staying asleep, even though such use is not recommended.

Olanzapine has been recommended to be used in antiemetic regimens in people receiving chemotherapy that has a high risk for vomiting.

Olanzapine is associated with the highest placental exposure of any atypical antipsychotic.

Olanzapine has demonstrated carcinogenic effects in multiple studies when exposed chronically to female mice and rats, but not male mice and rats.

Olanzapine is considered moderately toxic in overdose, more toxic than quetiapine, aripiprazole, and the SSRIs, and less toxic than the monoamine oxidase inhibitors and tricyclic antidepressants.

Olanzapine was first discovered while searching for a chemical analog of clozapine that would not require hematological monitoring.

Olanzapine has a higher affinity for 5-HT2A serotonin receptors than D2 dopamine receptors, which is a common property of most atypical antipsychotics, aside from the benzamide antipsychotics such as amisulpride along with the nonbenzamides aripiprazole, brexpiprazole, blonanserin, cariprazine, melperone, and perospirone.

Olanzapine had the highest affinity of any second-generation antipsychotic towards the P-glycoprotein in one in vitro study.

Olanzapine is metabolized by the cytochrome P450 system; principally by isozyme 1A2 and to a lesser extent by CYP2D6.

Olanzapine is unusual in having four well-characterised crystalline polymorphs and many hydrated forms.

Olanzapine denied these allegations and stated that the article had been based on cherry-picked documents.

Olanzapine is generic and available under many trade names worldwide.

Olanzapine is marketed in a number of countries, with tablets ranging from 2.

Olanzapine has been studied as an antiemetic, particularly for the control of chemotherapy-induced nausea and vomiting.

Olanzapine has been considered as part of an early psychosis approach for schizophrenia.

Olanzapine was effective for treating the prodromal symptoms, but was associated with significant weight gain.